Huston Thad Allen 4

What Happened

• Thad Allen, Chief Financial Officer of Artiva Biotherapeutics (ARTV), received a grant of 220,000 restricted stock units (RSUs) on March 10, 2026. The reported acquisition price is $0.00, reflecting an award (not a cash purchase). The filing lists this as an award/grant (transaction code A).

Key Details

• Transaction date: 2026-03-10; reported acquisition price per share: $0.00 (award).
• Award size: 220,000 RSUs.
• Shares owned after transaction: not specified in this filing.
• Footnote: RSUs granted under the Issuer’s 2025 Inducement Plan (per filing footnote).
• Filing timeliness: report date equals transaction date (filed same day); no late filing indicated.
• Transaction code meaning: A = Award/Grant.

Context

• Restricted stock units are a form of equity compensation that convert to shares (subject to vesting and any plan conditions) and are typically used for hiring, retention, or performance incentives. An inducement-plan grant usually means the award was made outside the company’s standard equity plan to recruit or retain an executive. Awards are compensation events and do not reflect an open-market buy or sell.